CRISPR minimizes environmental footprint, avoids traditional GMO’s in which foreign DNA infiltrates genes, aids family-owned farms with breeding techniques that lower the risk of disease, meets global demand for a diversified diet and reduces energy consumption associated with inefficient farmed fishing methods.
Related: Is a Medicare Plan Necessary?
ARKG “outperformed during the second quarter thanks to molecular diagnostic and sequencing as well as CRISPR genome editing stocks,” according to ARK research. “Intellia Therapeutics (NTLA), one of three public CRISPR genome-editing pure plays, contributed 295 bps to ARKG after securing two key CRISPR/Cas9 patents in the US and announcing its first cell therapy target for the treatment of acute myeloid leukemia.”
ARKG, which typically holds 30 to 50 stocks, has $204 million in assets under management and charges 0.75% per year.
For more information on the healthcare sector, visit our healthcare category.